<DOC>
	<DOCNO>NCT02981615</DOCNO>
	<brief_summary>Infections major prevalent life-threatening complication among patient myelodysplastic syndrome ( MDS ) . Currently , role prophylactic antibacterial agent chemotherapy MDS patient remain controversial clinical guideline infection prophylaxis clinical setting . We conduct prospective study evaluate potential benefit prophylactic antibacterial ( Levofloxacin ) rate febrile episodes/infections Azacytidine treat MDS patient .</brief_summary>
	<brief_title>Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis Azacitidine Treated MDS Patients</brief_title>
	<detailed_description>This national , multicenter , phase III , randomize , parallel arm , double blind , placebo control clinical trial evaluate efficacy safety antibacterial prophylaxis - Levofloxacin 500mg/d give p.o.in newly diagnose MDS patient 18 year age fulfil indication Azacytidine treatment . Patients treat 4 cycle Levofloxacin , placebo . Subjects allocate treatment arm study administrate Levofloxacin 500mg/d give p.o . day , start day 10 begin cycle day 28 . Subject allocate placebo arm treat placebo day , start day 10 begin cycle day 28 . Levofloxacin placebo treatment continue first 4 Azacytidine cycle . This study consist 3 period study subject : pre-treatment period , treatment period follow period . Expected duration subject participation 6 month Pre-treatment period : Assessments : MDS evaluation bone marrow examination include cytogenetics/ FISH must perform within half year first dose study drug .</detailed_description>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Age &gt; 18 year time signing informed consent document . 2 . Have document diagnosis primary secondary MDS accord WHO 2008 classification ( appendix I ) , fulfil indication Azacytidine treatment . 3 . Females childbearing potential ( FCBP ) may participate , provide meet following condition : Agree use least two effective contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intra uterine device ; barrier contraceptive spermicide ; vasectomized partner ) throughout study , 3 month follow last dose study drug ; negative serum urine pregnancy test ( investigator 's discretion ; sensitivity least 25 mIU/mL ) screening ; negative serum urine pregnancy test ( investigator 's discretion ) within 72 hour prior start study therapy treatment phase ( note screen serum pregnancy test use test prior start study therapy treatment phase perform within 72hour time frame ) . 4 . Male subject female partner childbearing potential must agree use least two physicianapproved contraceptive method throughout course study avoid father child course study 3 month follow last dose study drug . 5 . Understand voluntarily sign informed consent document prior study related assessments/procedures conduct . 6 . Able adhere study visit schedule protocol requirement . Prior treatment follow : 1.1 . Azacitidine ( formulation ) , decitabine hypomethylating agent 1.2 . Lenalidomide 2 . Prior allogeneic autologous stem cell transplant 3 . Use hydroxyurea within 7 day prior randomization . 4 . Diagnosis AML ( i.e . &gt; 30 % blast bone marrow ) . 5 . Ongoing adverse event previous treatment , regardless time period . 6 . Systemic fungal , bacterial , viral infection ( define ongoing signs/symptoms related infection without improvement despite appropriate antibiotic , antiviral therapy , and/or treatment ) 7 . Known Human Immunodeficiency Virus ( HIV ) 8 . Known suspected hypersensitivity azacitidine mannitol . 9 . Known suspected hypersensitivity Levofloxacin . 10 . Pregnant lactating female . 11 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 12 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 13 . Participation investigational drug trial last month randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>